Novartis provides update on Phase III CANOPY-A study
Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small...
Source: globenewswire.com
Page 5 - Hematology Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hematology Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hematology Development Today - Breaking & Trending Today
Novartis: Phase III CANOPY-A Study Evaluating Canakinumab Fails To Meet Primary Goal
BASEL (dpa-AFX) - Swiss drug major Novartis AG (NVS) announced Monday that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885) did not meet its primary endpoint
Source: finanznachrichten.de
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer | Antibodies
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
Source: pipelinereview.com
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...
Source: prnewswire.com
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Source: investegate.co.uk